<DOC>
	<DOCNO>NCT00903162</DOCNO>
	<brief_summary>The purpose study determine safety tolerability combination two drug ( letrozole leuprolide ) woman already take tamoxifen least 4.5 year . Letrozole , aromatase inhibitor ( block enzyme produce estrogen ) , drug FDA approve . It show reduce risk breast cancer recurrence postmenopausal woman breast cancer previously treat tamoxifen . Letrozole work stop production estrogen part body ovary . Leuprolide drug stop woman 's ovarian cycle . This process know ovarian function suppression . Stopping woman 's menstrual cycle may effective breast cancer patient give initial therapy . The combination letrozole leuprolide consider standard treatment woman metastatic breast cancer , also sometimes used treatment premenopausal early stage breast cancer , accept standard care treatment .</brief_summary>
	<brief_title>Extended Endocrine Therapy Premenopausal Women With Breast Cancer</brief_title>
	<detailed_description>- Participants give monthly intramuscular injection leuprolide . Six eight week first leuprolide injection , participant instruct begin take letrozole pill mouth home day . - During research study , participant also offer injection zoledronic acid preserve bone mineral density . If desire , injection give every 6 month total 4 injection course research study . - The treatment research study may increase risk bone density loss , vitamin D calcium supplement recommend participant . - The following test procedure perform research study : Physical Exam ( every visit ) ; Blood test ; Urine test ( begin end treatment ) ; Imaging ( annual mammogram ) ; Bone Density ( DXA ) Scan ( begin end treatment ) ; Questionnaires ( throughout study ) . - Participants study two year .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Leuprolide</mesh_term>
	<mesh_term>Letrozole</mesh_term>
	<mesh_term>Zoledronic acid</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>Women 18 year age old History invasive ER+ PR+ breast cancer treat least 4.5 year tamoxifen No current evidence recurrent invasive disease metastatic disease . Patients may history bilateral breast cancer Premenopausal ( estradiol level premenopausal range , &gt; 20pg/ml , within prior 28 day ) Liver function test creatinine &lt; 2.5 time upper limit normal within 28 day prior enrollment ECOG Performance Status 01 Must agree use nonhormonal contraception ( condom , diaphragm , IUD , sterilization , abstinence , etc ) hormonal therapy trial 3 month letrozole stop Negative pregnancy test within 14 day prior enrollment Patient must able speak , read write English Previous treatment oral IV bisphosphonate prior two year History cancer breast cancer within 5 year exclude basal/squamous cell skin carcinoma situ cervix Women evidence current local recurrence metastatic breast cancer Pregnant woman Nursing woman Women currently take tamoxifen unwilling stop medication Women know deleterious BRCA 1 BRCA 2 mutation</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>hormone-receptor positive</keyword>
	<keyword>tamoxifen</keyword>
	<keyword>letrozole</keyword>
	<keyword>zoledronic acid</keyword>
	<keyword>leuprolide</keyword>
</DOC>